LCTX Lineage Cell Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 876343 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.2%
TTM net income YoY102.6%
TTM EPS YoY69.0%
Revenue 3-yr CAGR7.3%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-280.3%
Net margin16.2%
FCF margin-244.1%
EBITDA margin-273.3%
Returns
ROE3.9%
ROA1.8%
ROIC (approx.)-216.8%
Asset turnover0.11x
Leverage & solvency
Liabilities / assets34.1%
Debt / equity0.00x
Current ratio5.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-14.73x
Accruals ratio29.1%
Payout ratio—
Capex / revenue5.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.43M | $1.07M | $1.73M | $6.61M | $3.68M | $2.77M | $1.50M | $2.87M |
| Cost of revenue | — | — | — | — | — | — | $36,000 | $154,000 |
| Gross profit | — | — | — | — | — | — | $1.47M | $2.71M |
| R&D expense | $3.82M | $4.77M | $4.23M | $8.24M | $3.27M | $3.11M | $3.11M | $3.42M |
| SG&A expense | $4.92M | $5.22M | $5.08M | $4.85M | $4.19M | $4.56M | $4.86M | $4.40M |
| Operating income | -$7.31M | -$8.92M | -$7.59M | -$6.55M | -$3.79M | -$19.78M | -$6.50M | -$5.11M |
| Pretax income | $4.71M | — | — | -$4.39M | -$29.75M | — | — | -$3.25M |
| Income tax | $484,000 | — | — | -$5.28M | $0 | — | — | $0 |
| Net income | $4.23M | $1.48M | -$4.81M | $851,000 | -$29.78M | -$30.46M | -$4.14M | -$3.27M |
| EBITDA | -$7.11M | -$8.74M | -$7.41M | -$6.36M | -$3.61M | -$19.61M | -$6.34M | -$4.96M |
| EPS (basic) | 0.02 | 0.01 | -0.02 | — | -0.13 | -0.13 | -0.02 | — |
| EPS (diluted) | -0.03 | -0.03 | -0.03 | — | -0.13 | -0.13 | -0.02 | — |
| Weighted avg. shares (diluted) | 259.07M | 261.47M | 261.18M | — | 228.85M | 228.36M | 226.05M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $26.50M | $37.35M | $35.94M | $40.79M | $40.46M | $42.27M | $47.89M | $46.35M |
| Short-term investments | $18.68M | $13.47M | $17.44M | $14.99M | $23,000 | $17,000 | $19,000 | $2.02M |
| Receivables | $1.33M | $790,000 | $806,000 | $891,000 | $127,000 | $256,000 | $213,000 | $638,000 |
| Current assets | $47.77M | $52.97M | $56.16M | $59.16M | $42.26M | $43.84M | $49.98M | $51.00M |
| PP&E, net | $2.38M | $2.52M | $2.50M | $2.57M | $2.16M | $2.25M | $2.15M | $2.25M |
| Goodwill | $10.67M | $10.67M | $10.67M | $10.67M | $10.67M | $10.67M | $10.67M | $10.67M |
| Intangibles | $31.70M | $31.70M | $31.70M | $31.70M | $31.70M | $31.70M | $46.54M | $46.54M |
| Total assets | $100.11M | $106.22M | $109.53M | $112.58M | $89.64M | $90.80M | $111.75M | $113.22M |
| Current liabilities | $8.02M | $8.02M | $8.15M | $11.37M | $9.38M | $10.76M | $13.09M | $13.98M |
| Total liabilities | $34.17M | $46.42M | $56.84M | $69.24M | $68.84M | $43.69M | $34.10M | $36.21M |
| Shareholders' equity | $67.06M | $60.92M | $53.88M | $44.55M | $22.04M | $48.38M | $79.03M | $78.38M |
| Shares outstanding | 252.91M | 252.91M | 249.30M | 243.12M | 230.33M | 228.36M | 228.36M | 220.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$5.62M | -$7.24M | -$8.08M | -$4.88M | -$3.62M | -$5.54M | -$4.89M | -$6.35M |
| Capital expenditure | $74,000 | $108,000 | $55,000 | $399,000 | $12,000 | $14,000 | $97,000 | $365,000 |
| Free cash flow | -$5.69M | -$7.35M | -$8.13M | -$5.28M | -$3.63M | -$5.55M | -$4.98M | -$6.71M |
| Investing cash flow | -$5.15M | $3.96M | -$2.33M | -$15.33M | -$12,000 | -$14,000 | $1.90M | $2.63M |
| Financing cash flow | -$23,000 | $4.47M | $5.56M | $20.38M | $1.83M | -$307,000 | $5.04M | $21.73M |
| Depreciation & amortization | $202,000 | $187,000 | $188,000 | $186,000 | $178,000 | $171,000 | $164,000 | $151,000 |
| Stock-based compensation | $1.70M | $1.60M | $1.17M | $1.10M | $1.20M | $1.24M | $1.22M | $1.31M |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.